Introduction
Antiepileptic drugs (AEDs) are widely used. They are prescribed as standard treatment not only for epilepsies, but for a variety of nonepileptic conditions as well, mainly bipolar spectrum disorders and chronic pain states. 1, 2 In fact, only one out of three AED users takes these drugs for epilepsy. 3, 4 A large number of AEDs are available. Since 1990, 16 new (or ''second-generation'') AEDs have been registered: lamotrigine, vigabatrin, tiagabine, felbamate, topiramate, gabapentin, pregabalin, levetiracetam, zonisamide, stiripentol, oxcarbazepine, eslicarbazepine, rufinamide, lacosamide, retigabine, and perampanel. In many countries, women constitute the majority of users of these new AEDs. [5] [6] [7] This may be due to special, women-related safety and tolerability issues, but as well to the epidemiology of certain disease states. 8, 9 During the past 20 years, much attention has been directed toward AEDs and women. Hormonal and metabolic disturbances induced by AEDs, as well as teratogenic and adverse cognitive effects in the offspring of women with epilepsy have come into the spotlight. [10] [11] [12] [13] Other women-specific questions such as drug interactions with hormonal contraception, the menstrual cycle, pharmacokinetic changes during pregnancy, breast-feeding, and menopause have also received growing attention. [14] [15] [16] [17] [18] Many studies on these issues have been conducted with the classic AEDs, mainly valproate and carbamazepine. With respect to the newer antiepileptic drugs however, only lamotrigine appears to be comparably well-studied. Other new AEDs have been examined only in part, or not at all. Generally, and with only few exceptions (e.g., felbamate and vigabatrin), the new AEDs possess favorable safety profiles compared to the classic AEDs. Especially concerning hormone-related issues and teratogenicity, the new AEDs appear to come out better than the older AEDs. 19 Accordingly, the use of new AEDs by fertile women has increased considerably. 20 Many of the studies discussed in this review, although useful, are small and do not qualify as basis for sound clinical guidelines. Their results should be reproduced by further, and preferably larger, studies. In fact, there are still too many gaps in our knowledge and much research remains to be done. Nonetheless, this review aims to give a brief yet concise overview on what is currently known, and what is not, on the clinical pharmacokinetics of new AEDs in women. Possible effects on the offspring of women treated with new AEDs (teratogenic or cognitive) will not be covered.
Since 1990, sixteen new antiepileptic drugs (AEDs) have been introduced. Most of these new AEDs have only been insufficiently studied with respect to women-specific aspects such as endogenous sex hormones, hormonal contraception, pregnancy, breastfeeding, or menopause. This is of concern because it has been shown for some of the new AEDs that these factors may have a clinically significant impact on their pharmacokinetics and seizure control. Also, new AEDs may affect hormone homeostasis and pass over into breast milk. The best studied of the new AEDs are lamotrigine, levetiracetam and oxcarbazepine. Although gabapentin and pregabalin are even more frequently used (due to their therapeutic effects in nonepileptic conditions), our understanding of these two drugs in relation to women's issues is surprisingly poor. Little to nothing is known about zonisamide, retigabine/ezogabine, lacosamide, perampanel and the other new AEDs. Nevertheless, many small studies and case series have been published on new AEDs and women-specific aspects. This review gives an overview on what is known today.
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Sex hormones

Endogenous female sex hormones
Female sex hormones can roughly be divided into estrogens and progestogens, and both of them can be of endogenous or exogenous origin. Estrogens have long been seen as pro-convulsive compounds while progestogens are generally thought to have anticonvulsive effects. [21] [22] [23] [24] [25] While this implies a theoretical possibility of pharmacodynamic interactions with AEDs, things are not that simple. Estrogens may have neuroprotective and anti-convulsive effects as well. Their effects may depend on the body's general hormonal state, and fluctuations in the serum level ratio between estrogens and progestogens also seem to be of great relevance for the biological effects of estrogens. 25 Thus, with our limited knowledge, any net effect of the theoretical pharmacodynamic interactions between estrogens, progestogens and AEDs would be difficult to evaluate or predict. Pharmacokinetic effects of endogenous female sex hormones on new AEDs are most relevant with respect to the menstrual cycle and pregnancy. These issues are discussed in separate sections below.
There are only very few studies on how new AEDs may exert effects on endogenous female sex hormones. Oxcarbazepine has been reported to decrease endogenous estrogen by 50% and progesterone by 58%. 26 For lamotrigine, only small and hardly clinically relevant changes (reduced estradiol and increased progesterone) have been found. 27 Levetiracetam does not seem to induce changes in female sex hormone status in prepubertal children or adult women. 28, 29 There seem to be no published human studies investigating possible effects of topiramate, gabapentin, pregabalin or any of the other new AEDs on endogenous female sex hormones.
Exogenous female sex hormones
Exogenous female sex hormones are predominantly used in hormonal contraception and in hormonal replacement therapy (HRT). These are discussed in separate sections.
Endogenous male sex hormones
Women do produce male sex hormones. The most important ones are testosterone, androstendione, and dihydroepiandrosterone (DHEA). Alterations in their production may have significant consequences, e.g. disturbed metabolism or impaired fertility.
Testosterone is metabolised to estradiol by aromatase, and it has been assumed that levetiracetam may inhibit aromatase. If this is true, patients on levetiracetam may have raised testosterone levels, accompanied by reduced estradiol levels. In fact, this has been found in an in vitro study. 30 However, the only available study that investigated androgen and estrogen levels in women using levetiracetam found no differences vs. untreated controls. 28 Lamotrigine apparently does not alter testosterone levels when compared to untreated controls or valproate-treated patients. 28, 31, 32 However, slightly reduced androstendione (22%) and elevated DHEA (30%) levels have been reported. 28 Oxcarbazepine reduces testosterone levels by 25%, while DHEA and androstendione levels go up by 30% and 20%. 26 In conclusion, with the exception of oxcarbazepine's effects on estradiol and progesterone, the impact of new AEDs on endogenous hormones -as far as they have been studied -seems to be rather moderate.
Sex hormone binding globulin
Sex hormone binding globulin (SHBG) is a liver-derived glycoprotein that transports sex hormones and regulates their access to target tissues. 33 AED-induced changes in SHBG levels may thus be relevant for sex hormone functioning and homeostasis. Lamotrigine has been shown not to affect SHBG levels significantly, 27, 28, 32, 34 although Hill et al. 27 and Sidhu et al. 34 found lowered values in lamotrigine-treated women vs. controls. Likewise, levetiracetam does not seem to affect SHBG levels. 28 By contrast, oxcarbazepine increases SHBG by 10-20%. This effect may contribute to the lower levels of estradiol and progesterone found with oxcarbazepine treatment. 26 No data on SHBG in women are available for the other new AEDs.
Menstrual cycle
Estradiol up-regulates the expression of uridinediphosphateglucuronosyltransferase (UGT) 1A4. 35 This enzyme catalyzes the metabolism of lamotrigine, and also retigabine/ezogabine. As shown by Sidhu et al. 34 (discussed below), the estrogen-mediated induction of UGT1A4 vanishes within a few days after stopping the intake of ethinyl estradiol containing contraceptives, and lamotrigine serum concentrations may double within one week. Similarly, physiological serum concentrations of endogenous estradiol vary considerably during the menstrual cycle. Extrapolating the findings of Sidhu et al. 34 one might expect similar ups and downs of lamotrigine levels. However, several studies show that fluctuating serum concentrations of endogenous estradiol or progesterone during the menstrual cycle do not affect lamotrigine serum concentrations in a clinically relevant manner. [36] [37] [38] Neither retigabine/ezogabine (also a UGT-substrate) nor any of the other new AEDs have been studied in this regard. However, during the luteal phase of the menstrual cycle, renal blood flow, glomerular filtration rate and body water may increase by up to 10%. 39 As is the case with, e.g. serum sodium or serum albumin, serum concentrations of most drugs, especially those with primarily renal elimination (e.g., gabapentin, pregabalin or levetiracetam) may decline accordingly, i.e. by a magnitude of 5-10%. Such changes are so small that they have to be regarded as clinically irrelevant. Unfortunately, as mentioned above, there is a substantial lack of data supporting these considerations.
Hormonal contraception
Effects of new AEDs on hormonal contraception
It is well known that traditional AEDs like phenytoin or carbamazepine can reduce the effect of hormonal contraception via induction of cytochome enzymes. Thus, it has become standard procedure during the development of new AEDs to examine their possible effects on hormonal contraception. Many of the new AEDs have been tested for possible impairment of hormonal contraception (Table 1) . Lamotrigine, levetiracetam, gabapentin, zonisamide, lacosamide, perampanel and retigabine do not alter the serum concentrations of ethinyl estradiol. 34, [40] [41] [42] [43] [44] [45] [46] Also, with the exception of lamotrigine and perampanel, they do not affect the serum concentrations of exogenous progestogens like levonorgestrel. 34, 40 The effect of the latter two AEDs on progestogen levels seems to be rather modest. However, the possibility of decreased contraceptive efficacy cannot be excluded. 47, 48 Oxcarbazepine and eslicarbazepine reduce exposure to both ethinyl estradiol and progestogens considerably, making hormonal contraception unreliable. 49, 50 Topiramate is a moderate enzyme inducer. It has been examined in two studies, and in neither of them did it affect the kinetics of progestogens. With respect to ethinyl estradiol, one of these studies found no effect at daily topiramate doses of 50, 100 and 200 mg. However, the other study examined daily doses of 200, 400 and 800 mg, and here the maximum ethinyl estradiol serum concentration was reduced by topiramate at 400 mg and 800 mg daily.
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Effects of hormonal contraception on new AEDs
Sabers et al. 53 and others 34, 54 demonstrated that oral contraceptives containing ethinyl estradiol can reduce the serum concentration of lamotrigine by over 50%, leading to breakthrough seizures and requiring dose adjustment. Progestogen-only contraceptives do not seem to affect lamotrigine pharmacokinetics significantly. 54 Despite its clinical relevance, this kind of drug interaction has received only modest attention. Levetiracetam, zonisamide, lacosamide and (somewhat surprising with regard to its UGT-mediated metabolism) retigabine/ezogabine have been found not to be affected by hormonal contraceptives. 41, 42, 44, 45, 55 No studies on the other new AEDs are available (Table 1) .
Pregnancy
During pregnancy, significant changes in several physiological functions occur [56] [57] [58] and some of them will affect the pharmacokinetics of drugs given to the pregnant patient. 15, 16, 59 The most relevant changes are (a) an increase by 50-80% of renal blood flow shortly after conception (b) a massive increase in the serum concentration of endogenous estrogens and (c) an increase in total body water and fat stores Renal blood flow increases significantly as early as two weeks after conception and may lead to accelerated renal elimination of drugs, especially those that are excreted mainly unchanged through the kidneys. Raised estrogen levels lead to changes in metabolic capacity: dependent on the isoform, both increased and decreased activities of cytochome P450 (CYP) enzymes have been found. More importantly, raised estrogen induces the activity of UGT enzymes considerably. 35, 58 This may lead to clinically relevant alterations in drug metabolism. Increased total body water and body fat may result in larger volumes of distribution and lower AED serum concentrations. Also, serum albumin concentrations decline considerably during pregnancy. However, lowered serum albumin usually affects drugs that are highly protein bound (>90%), leading to increases in their free (=pharmacologically active) fraction. Of the new AEDs, this applies to tiagabine and stiripentol. Unfortunately, no data on the course of their serum concentrations during pregnancy are available. 60 In addition to these changes, frequent vomiting makes drug absorption uncertain in many women. The physiological changes induced by pregnancy are usually reversed within 1-2 weeks after childbirth. Changes in drug metabolism and elimination will also be reversed within this time frame, and serum concentrations that declined during pregnancy will rise after delivery. If dose adjustments were made during pregnancy, they must be reversed shortly, in order to prevent overdosing. Therapeutic drug monitoring is recommended. 59, 61 Lamotrigine is by far the best studied of all the new AEDs. Its serum concentrations decline by 40-60% during pregnancy, and most of this decline occurs already within the first trimester. Loss of seizure control occurs in up to 58% of pregnant women, and dose adjustment often becomes necessary. [62] [63] [64] [65] [66] [67] [68] [69] [70] [71] Both increased renal elimination and increased metabolism contribute to this effect. 62, 65, 72 Serum concentrations turn back to pre-pregnancy levels within one to two weeks after delivery. An easy-to-follow algorithm for dose adjustment during pregnancy and its reversal after childbirth has been developed. 61 Levetiracetam serum concentrations fall by 40-60% during pregnancy, most presumably due to accelerated renal elimination. 59, 73, 74 After delivery, concentrations raise to pre-pregnancy levels within one week. 73 Topiramate concentrations decline by 30-40%, most likely due to accelerated renal elimination. 75, 76 No serum concentrations have been measured within the first weeks after delivery, but one should expect a rapid reversal of pregnancy-induced changes in topiramate elimination, i.e. within 1-2 weeks. Oxcarbazepine, or more precisely: its active metabolite licarbazepine (formerly called monohydroxyderivative, or MHD), declines by 30-40%. [77] [78] [79] The most active enantiomer of licarbazepine, S-licarbazepine (marketed as eslicarbazepine acetate), has not been studied separately. Because eslicarbazepine obviously follows the same elimination pathways as licarbazepine (i.e., mainly glucuronidation), a similar decline of its serum concentrations should be expected. This is supported by stereoselective measurements performed in a series of five patients treated with oxcarbazepine by Mazzucchelli et al. 77 In this case series, serum concentrations of S-licarbazepine increased 1.5-13-fold within a few days after delivery. A similar trend was seen for Rlicarbazepine. Zonisamide has not been studied systematically, but two case reports suggest that serum concentrations fall by 20-40% during pregnancy. 80, 81 In one of these cases, the plasma concentration was measured after childbirth, and it rose by 45% within 9 days postpartum. 80 Data on other new AEDs in pregnancy are not available (Table 2 ). It appears reasonable to assume that these drugs also are subject to more or less accelerated elimination from the body. Especially the serum concentrations of gabapentin, pregabalin and lacosamide (eliminated mainly unchanged via the kidneys) and retigabine/ezogabine (eliminated mainly by glucuronidation) should be expected to decline considerably.
Apart from the physiological changes leading to altered pharmacokinetics of new AEDs, one should keep in mind that adherence may have an even greater impact. 82 Several studies have shown that 40-60% of pregnant women do not take their medication as prescribed, and this has also been found in women with epilepsy.
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Breastfeeding
New AEDs, like other drugs, pass over into breast milk, although to varying degrees according to their individual physicochemical properties. Only a limited number of small-scaled studies and 66, 87 and correlates with the mother's dose. 88 Neonatal lamotrigine serum concentrations are approximately equivalent to maternal lamotrigine concentrations at delivery. By contrast, the ratio of nursed infant/maternal serum lamotrigine concentrations is much lower and varies greatly, from 0.03 to 0.5. This does not seem to be related to the infant's age. 63, 69, 70, 88 Possible causes include not only variable lamotrigine concentrations in breast milk, but also large interindividual differences in UGT1A4-mediated metabolic capacity up to the teen-age years (the younger the age, the greater the variability). 89 Indeed, it has been suggested that full UGT1A4 activity may not be reached before almost 19 years of age. 90 In sum, over 50 mother/infant pairs have been documented so far. 66, [68] [69] [70] 87, 88, [91] [92] [93] [94] [95] With only one exception, no adverse effects have been noted in these studies. The exception is a case report that describes an episode of apnoea in a breastfed child whose mother used a dose of 850 mg lamotrigine (increased from 450 mg during pregnancy). 95 At admission, 16 days postpartum, the infant's serum concentration was 4.9 mg/ml.
However, on the day of birth and on postpartum day 3, infant serum concentrations were even higher (7.7 mg/ml and 5.8 mg/ ml), but without any signs of respiratory depression or other adverse effects. This appears to be the only available report on acute adverse effects of breastfeeding while using lamotrigine and it should be noted that the dose used by the mother was relatively high. The maternal serum concentration on the day after admission of the infant was 14.9 mg/ml. Hence, the infant/mother serum concentration ratio was 0.3, which is within the usual range as reported by other authors. This case underlines the need to monitor maternal serum concentrations and to reduce the lamotrigine dose after delivery. Possible cognitive effects have been investigated in a recent study with long-term follow-up. No difference in mean IQ between 30 breastfed and 36 non-breastfed children at age three years was found. 96 Levetiracetam shows extensive transfer into breast milk and in two studies, the milk/maternal serum concentration ratio averaged around 1. Breast-fed infants had low levetiracetam serum concentrations, suggesting a rapid elimination of the drug. No adverse effects were noted. 74, 97 By contrast, a single case report described increasing hypotonia and poor suckling in a 7 days old infant (born pre-term at 34 weeks of gestation) after levetiracetam had been added to his mother's treatment regime. In this case, the milk/plasma ratio was 3.1. No infant serum concentrations were measured at admission. 98 From the sparse data available, the milk/maternal plasma concentration ratio of the active metabolite of oxcarbazepine, licarbazepine (MHD), is 0.5-0.8. 99, 100 However, serum concentrations in the reported infants did not exceed 5% of the mother's plasma levels and no harmful effects have been reported. [99] [100] [101] [102] [103] [104] No separate studies on eslicarbazepine have been published. Limited data suggest that topiramate is safe for breastfeeding. The milk/maternal plasma concentration ratio averages around 0.9, but serum concentrations in the infants were very low. No adverse effects on breastfed children have been reported. 105, 106 Only four mother/infant pairs have been reported with respect to zonisamide. The calculated milk/maternal serum concentration ratios ranged from 0.7 to 0.9. 80, 107, 108 No adverse effects on the breastfed child have been reported. However, because of the comparably high relative infant dose (about 30%) reported in these cases, caution and close monitoring of the infant is advisable. Gabapentin concentrations in breast milk resemble the mother's plasma concentrations, with a milk/plasma ratio of 0.7-1.3. Infant plasma concentrations ranged from 6 to 12% of the mother's plasma concentration. No side effects in breastfed children have been observed, but only six mother/infant pairs are documented. 109, 110 There are no studies or case reports on the other new AEDs.
Menopause/hormone replacement therapy
Hormone substitution with natural or synthetic estrogens is very common in postmenopausal women. It has been reported that 50-71% of postmenopausal women with epilepsy experience a worsening of their seizures, and that the degree of worsening correlates with the estrogen dose. 111 This may be due to endocrine changes, but may also be a consequence of drug interactions between exogenous estrogens and AEDs. 112 Three studies found lower lamotrigine serum concentrations and a higher clearance in postmenopausal women. 38, 112, 113 It might seem obvious that hormone substitution with estrogens may play a role. However, in one of these studies, 38 use of steroid hormones was an exclusion criterion. Further studies are needed to clarify this. One study found that oxcarbazepine clearance does not seem to be affected by perimenopausal age. 114 No further data have been published. No other studies on interactions between new AEDs and menopause or hormone replacement could be identified.
Bone health
Reduced bone mineral density and increased risk of fractures is a common adverse effect in women after long-term treatment with traditional AEDs. 115, 116 Clinical data on the new AEDs are sparse. While a large retrospective cohort study (n = 15 792) reported an elevated bone fracture risk for gabapentin but none of the other new AEDs studied (including lamotrigine, levetiracetam and oxcarbazepine), 117 a smaller study with 560 participants (also retrospective) concluded that new AEDs are not associated with lower bone mineral density. 118 Other published data as well are conflicting. [119] [120] [121] [122] [123] [124] . However, in an animal model, levetiracetam has been shown to impair bone quality but not bone density, suggesting that standard measurement of bone mineral density may not detect all AED-induced changes in bone health. 125 Further, prospective clinical studies, ideally with clinical outcome parameters such as bone fracture frequency, are needed in this field before any conclusions can be drawn. n.a. = no data available.
Conclusion
Much research has been done, but even more research is needed. The speed at which new AEDs have been released during the past 20 years has led to a large number of available drugs which we know relatively little about when it comes to women-specific questions. As much as this review has tried to sum up the available knowledge, it has demonstrated how much we do not know (yet). Compared to traditional AEDs like phenytoin, phenobarbital or carbamazepine, most of the new AEDs have a more favorable safety profile even if some of them may affect hormone homeostasis or can induce serious adverse effects (e.g. felbamate, vigabatrin). Their clinical pharmacokinetics, however, may not be so favorable. Several womenspecific factors may affect their serum concentration, and for many clinicians, therapeutic drug monitoring during pregnancy has virtually become a necessity. Finally, the example of lamotrigine serum concentrations being reduced by ethinyl estradiol containing contraceptives (discovered as late as 10 years after lamotrigine came onto the market) illustrates that future research on new AEDs and women may profit from new ways to look at things.
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